FREELINE - Trademark Details
Status: 700 - Registered
Image for trademark with serial number 79255127
Serial Number
79255127
Registration Number
5999142
Word Mark
FREELINE
Status
700 - Registered
Status Date
2020-03-03
Filing Date
2018-11-23
Registration Number
5999142
Registration Date
2020-03-03
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2019-12-17
Attorney Name
Samantha M. Quimby
Law Office Assigned Location Code
M70
Employee Name
BUCHANAN WILL, NORA
Statements
Goods and Services
Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases
Pseudo Mark
FREE LINE
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2019-03-27
Primary Code
005
Current Trademark Owners
Party Name
Freeline Therapeutics Limited
Party Type
30 - Original Registrant
Legal Entity Type
99 - Other (Limited Company/LLP UK, England and Wales).
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Freeline Therapeutics Limited
Party Type
30 - Original Registrant
Legal Entity Type
99 - Other (Limited Company/LLP UK, England and Wales).
Address
Please log in with your Justia account to see this address.
Party Name
Freeline Therapeutics Limited
Party Type
20 - Owner at Publication
Legal Entity Type
99 - Other (Limited Company/LLP UK, England and Wales).
Address
Please log in with your Justia account to see this address.
Party Name
Freeline Therapeutics Limited
Party Type
10 - Original Applicant
Legal Entity Type
99 - Other (Limited Company/LLP UK, England and Wales).
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Samantha M. Quimby
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship TypeReel Number
Prior Registration5225203
International Registrations
International Registration Number
1291109
International Registration Date
2016-01-29
International Publication Date
2019-03-21
International Renewal Date
2026-01-29
Auto Protection Date
2020-09-21
International Status
001 - Request for extension of protection established
International Status Date
2019-03-21
Priority Claimed In
False
First Refusal In
True
Trademark Events
Event DateEvent Description
2019-03-21SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
2019-03-25LIMITATION FROM ORIGINAL APPLICATION ENTERED
2019-03-27NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2019-03-27ASSIGNED TO EXAMINER
2019-04-02APPLICATION FILING RECEIPT MAILED
2019-04-16NON-FINAL ACTION WRITTEN
2019-04-17NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
2019-05-07REFUSAL PROCESSED BY MPU
2019-05-08NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
2019-06-14REFUSAL PROCESSED BY IB
2019-11-06TEAS RESPONSE TO OFFICE ACTION RECEIVED
2019-11-06CORRESPONDENCE RECEIVED IN LAW OFFICE
2019-11-06TEAS/EMAIL CORRESPONDENCE ENTERED
2019-11-07APPROVED FOR PUB - PRINCIPAL REGISTER
2019-11-12ASSIGNED TO LIE
2019-11-27NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2019-12-17PUBLISHED FOR OPPOSITION
2019-12-17OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2020-03-03REGISTERED-PRINCIPAL REGISTER
2020-06-03FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
2020-07-08FINAL DISPOSITION PROCESSED
2020-07-08FINAL DISPOSITION NOTICE SENT TO IB
2020-07-24FINAL DECISION TRANSACTION PROCESSED BY IB